

# Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	9.3	75.6	(30.3-155.7)	Male	3	6.4	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
Female	46	37.8	121.5	(89.0-162.1)	Female	9	4.3	209.8	(95.8-398.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.9	nc	(nc-nc)
Male	8	10.7	75.0	(32.3-147.8)	<b><u>Ovary</u></b>				
Female	9	9.2	97.9	(44.7-185.8)	Female	4	3.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.7	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	41	38.8	105.7	(75.9-143.4)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.3	nc	(nc-nc)
Male	7	5.7	123.5	(49.5-254.6)	Female	2	1.1	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.3	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	7.3	95.3	(38.2-196.3)
Male	2	3.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.5	nc	(nc-nc)	Female	11	8.9	122.9	(61.3-220.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.6	nc	(nc-nc)	Male	128	134.3	95.3	(79.5-113.3)
Female	0	1.0	nc	(nc-nc)	Female	143	122.2	117.0	(98.6-137.9)
<b><u>Lung and Bronchus</u></b>									
Male	22	17.5	125.4	(78.6-189.9)					
Female	22	16.4	134.3	(84.1-203.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	22.9	91.7	(56.7-140.2)	Male	6	15.0	40.1	(14.6-87.3)
Female	10	8.5	118.1	(56.6-217.3)	Female	9	11.3	79.7	(36.4-151.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.3	nc	(nc-nc)	Male	6	4.3	138.1	(50.4-300.5)
Female	5	3.5	143.3	(46.2-334.4)	Female	2	3.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	12	13.3	90.3	(46.6-157.8)
Female	72	84.2	85.5	(66.9-107.7)	Female	14	10.9	128.2	(70.0-215.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.9	nc	(nc-nc)	Male	14	10.5	133.1	(72.7-223.3)
<b><u>Colon / Rectum</u></b>					Female	4	4.5	nc	(nc-nc)
Male	22	25.5	86.2	(54.0-130.5)	<b><u>Ovary</u></b>				
Female	31	26.0	119.4	(81.1-169.5)	Female	7	7.8	89.7	(35.9-184.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	6.0	132.7	(57.1-261.4)	Male	10	7.7	129.2	(61.9-237.7)
Female	2	1.6	nc	(nc-nc)	Female	9	8.3	108.1	(49.3-205.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	70	78.9	88.7	(69.1-112.1)
Female	1	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	5.4	nc	(nc-nc)
Male	13	12.4	105.2	(55.9-179.9)	Female	5	3.3	151.1	(48.7-352.7)
Female	11	6.9	160.1	(79.8-286.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	3.3	152.9	(49.3-356.9)
Male	1	3.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	2	5.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	15.3	78.3	(40.4-136.8)
Male	9	9.2	98.0	(44.7-186.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	6.7	134.9	(61.5-256.0)	Female	26	18.8	138.4	(90.4-202.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	7.7	129.3	(61.9-237.8)	Male	273	302.8	90.2	(79.8-101.5)
Female	3	2.4	nc	(nc-nc)	Female	308	295.5	104.2	(92.9-116.6)
<b><u>Lung and Bronchus</u></b>									
Male	42	40.8	102.9	(74.2-139.1)					
Female	44	41.8	105.1	(76.4-141.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	7.8	nc	(nc-nc)	Male	7	5.5	128.3	(51.4-264.3)
Female	2	2.6	nc	(nc-nc)	Female	5	4.2	117.9	(38.0-275.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	4.8	167.3	(72.0-329.7)
Female	38	33.8	112.5	(79.6-154.4)	Female	5	3.7	133.9	(43.1-312.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.6	nc	(nc-nc)
Male	9	9.1	98.4	(44.9-186.8)	<b><u>Ovary</u></b>				
Female	7	8.0	87.1	(34.9-179.4)	Female	1	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	39	31.8	122.7	(87.2-167.7)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.9	nc	(nc-nc)
Male	9	4.8	187.0	(85.3-355.0)	Female	2	1.0	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.1	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	6.7	74.5	(24.0-173.9)
Male	3	3.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.2	nc	(nc-nc)	Female	8	7.7	103.9	(44.7-204.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	109	113.0	96.5	(79.2-116.4)
Female	1	0.8	nc	(nc-nc)	Female	125	107.6	116.2	(96.7-138.4)
<b><u>Lung and Bronchus</u></b>									
Male	8	14.8	54.2	(23.3-106.8)					
Female	25	14.2	175.8	(113.8-259.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gill

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	1.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	7	7.2	96.8	(38.8-199.4)	Female	0	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.4	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	1.9	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	10	7.5	132.6	(63.5-243.8)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.3	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	29	25.6	113.2	(75.8-162.6)
Female	0	0.2	nc	(nc-nc)	Female	27	23.6	114.6	(75.5-166.8)
<b><u>Lung and Bronchus</u></b>									
Male	6	3.4	178.2	(65.1-387.8)					
Female	7	3.2	220.8	(88.5-455.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	44	37.7	116.6	(84.7-156.6)	Male	34	24.1	141.1	(97.7-197.2)
Female	20	14.3	140.2	(85.6-216.5)	Female	27	19.0	142.3	(93.7-207.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	6.6	75.7	(24.4-176.7)	Male	6	7.2	83.5	(30.5-181.7)
Female	5	5.8	86.3	(27.8-201.4)	Female	3	6.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	24	21.1	113.7	(72.8-169.2)
Female	164	148.8	110.2	(94.0-128.5)	Female	18	18.7	96.4	(57.1-152.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.8	nc	(nc-nc)	Male	23	17.3	132.7	(84.1-199.1)
<b><u>Colon / Rectum</u></b>					Female	10	7.8	128.6	(61.6-236.5)
Male	51	41.2	123.8	(92.2-162.8)	<b><u>Ovary</u></b>				
Female	33	42.8	77.0	(53.0-108.2)	Female	15	13.7	109.6	(61.3-180.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	10.3	126.5	(67.3-216.4)	Male	18	12.9	139.3	(82.5-220.1)
Female	2	2.7	nc	(nc-nc)	Female	14	13.9	100.7	(55.0-169.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.6	nc	(nc-nc)	Male	141	139.9	100.8	(84.8-118.9)
Female	4	2.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	8.8	102.4	(46.7-194.5)
Male	18	20.3	88.8	(52.6-140.4)	Female	4	5.4	nc	(nc-nc)
Female	16	12.0	133.4	(76.2-216.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.9	nc	(nc-nc)
Male	9	5.7	158.3	(72.2-300.4)	<b><u>Thyroid</u></b>				
Female	3	1.9	nc	(nc-nc)	Male	8	8.9	90.3	(38.9-177.9)
<b><u>Leukemia</u></b>					Female	30	25.1	119.4	(80.5-170.5)
Male	25	14.4	173.5	(112.3-256.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	10.8	55.4	(20.2-120.5)	Female	27	34.8	77.6	(51.2-113.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	13.0	84.6	(42.2-151.4)	Male	576	503.5	114.4	(105.2-124.1)
Female	4	4.3	nc	(nc-nc)	Female	542	509.5	106.4	(97.6-115.7)
<b><u>Lung and Bronchus</u></b>									
Male	87	69.0	126.0	(100.9-155.5)					
Female	99	73.9	134.1	(109.0-163.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
Female	3	5.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.9	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	12	17.2	69.7	(36.0-121.8)
Female	0	0.1	nc	(nc-nc)	Female	9	16.0	56.1	(25.6-106.6)
<b><u>Lung and Bronchus</u></b>									
Male	0	2.3	nc	(nc-nc)					
Female	0	2.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.2	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Grafton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	15.7	101.9	(58.2-165.5)	Male	8	10.9	73.2	(31.5-144.2)
Female	4	5.6	nc	(nc-nc)	Female	9	9.1	99.0	(45.2-187.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	3.4	266.2	(121.5-505.3)	Male	5	3.1	160.1	(51.6-373.6)
Female	3	2.8	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	5	9.7	51.7	(16.7-120.7)
Female	75	68.7	109.2	(85.9-136.9)	Female	10	7.9	126.5	(60.5-232.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.7	nc	(nc-nc)	Male	12	8.1	148.6	(76.7-259.5)
<b><u>Colon / Rectum</u></b>					Female	3	3.4	nc	(nc-nc)
Male	14	18.3	76.3	(41.7-128.1)	<b><u>Ovary</u></b>				
Female	18	17.5	103.1	(61.1-162.9)	Female	6	6.1	97.7	(35.7-212.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	4.4	136.1	(49.7-296.3)	Male	6	5.5	109.2	(39.9-237.6)
Female	0	1.1	nc	(nc-nc)	Female	4	5.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	61	59.5	102.5	(78.4-131.7)
Female	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.8	nc	(nc-nc)
Male	10	9.4	105.9	(50.7-194.8)	Female	1	2.2	nc	(nc-nc)
Female	3	5.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.6	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	6	4.7	128.9	(47.1-280.6)
<b><u>Leukemia</u></b>					Female	11	14.4	76.4	(38.1-136.7)
Male	16	6.7	239.8	(137.0-389.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	4.8	165.5	(71.2-326.0)	Female	12	15.3	78.2	(40.4-136.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	5.8	104.1	(38.0-226.5)	Male	229	221.4	103.4	(90.5-117.7)
Female	0	1.8	nc	(nc-nc)	Female	222	224.9	98.7	(86.1-112.6)
<b><u>Lung and Bronchus</u></b>									
Male	33	28.7	115.0	(79.2-161.5)					
Female	33	29.5	111.8	(77.0-157.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	6.9	nc	(nc-nc)	Male	0	4.6	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.1	122.9	(39.6-286.7)
Female	17	27.6	61.6	(35.9-98.7)	Female	2	3.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.4	nc	(nc-nc)
Male	7	7.8	89.6	(35.9-184.5)	<b><u>Ovary</u></b>				
Female	5	7.1	70.4	(22.7-164.3)	Female	6	2.5	243.0	(88.7-528.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	24	26.4	90.8	(58.2-135.2)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.7	nc	(nc-nc)
Male	3	4.0	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.9	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	5.2	115.4	(42.1-251.2)
Male	1	2.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.9	nc	(nc-nc)	Female	9	6.3	142.9	(65.2-271.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.5	nc	(nc-nc)	Male	78	95.7	81.5	(64.4-101.7)
Female	1	0.7	nc	(nc-nc)	Female	74	90.4	81.8	(64.3-102.7)
<b><u>Lung and Bronchus</u></b>									
Male	13	12.8	101.3	(53.9-173.2)					
Female	12	12.5	96.3	(49.7-168.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	1.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	8	7.0	114.8	(49.4-226.2)	Female	0	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	1.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	10	7.2	138.9	(66.5-255.5)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	1.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	31	26.0	119.4	(81.1-169.5)
Female	0	0.2	nc	(nc-nc)	Female	27	22.4	120.6	(79.5-175.5)
<b><u>Lung and Bronchus</u></b>									
Male	3	3.4	nc	(nc-nc)					
Female	4	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	9.6	155.8	(87.2-257.1)	Male	12	5.9	202.5	(104.5-353.8)
Female	7	3.7	190.9	(76.5-393.3)	Female	5	4.7	106.6	(34.3-248.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.6	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
Female	31	36.4	85.2	(57.9-121.0)	Female	5	4.7	105.7	(34.1-246.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.0	nc	(nc-nc)
Male	6	10.3	58.5	(21.4-127.4)	<b><u>Ovary</u></b>				
Female	8	11.0	72.5	(31.2-143.0)	Female	2	3.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.5	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	3.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	36	33.3	108.2	(75.8-149.8)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.2	nc	(nc-nc)
Male	6	4.8	124.4	(45.4-270.7)	Female	1	1.4	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.9	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	5.9	168.1	(80.5-309.2)
Male	2	3.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.8	nc	(nc-nc)	Female	8	8.6	92.9	(40.0-183.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.1	nc	(nc-nc)	Male	127	123.4	102.9	(85.8-122.5)
Female	1	1.1	nc	(nc-nc)	Female	118	127.0	92.9	(76.9-111.3)
<b><u>Lung and Bronchus</u></b>									
Male	18	17.2	104.7	(62.0-165.5)					
Female	20	18.4	108.7	(66.3-167.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	20.7	96.6	(59.0-149.2)	Male	13	13.0	100.1	(53.2-171.2)
Female	8	8.6	93.1	(40.1-183.4)	Female	4	11.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.7	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	7	3.4	204.3	(81.8-421.0)	Female	3	3.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	5	11.6	43.2	(13.9-100.8)
Female	79	84.2	93.8	(74.3-117.0)	Female	11	11.0	99.9	(49.8-178.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.8	nc	(nc-nc)	Male	8	9.1	88.1	(37.9-173.6)
<b><u>Colon / Rectum</u></b>					Female	3	4.5	nc	(nc-nc)
Male	26	22.6	115.1	(75.2-168.7)	<b><u>Ovary</u></b>				
Female	29	26.3	110.4	(73.9-158.5)	Female	10	7.9	126.9	(60.8-233.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	5.4	93.4	(30.1-218.0)	Male	7	6.9	100.8	(40.4-207.6)
Female	0	1.6	nc	(nc-nc)	Female	6	8.5	70.3	(25.7-153.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	1.5	397.1	(145.0-864.3)	Male	60	70.4	85.2	(65.0-109.7)
Female	1	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.8	nc	(nc-nc)
Male	8	10.6	75.5	(32.5-148.8)	Female	5	3.4	148.7	(47.9-347.0)
Female	5	6.9	72.8	(23.4-169.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.5	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	1	4.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	14.7	nc	(nc-nc)
Male	4	8.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	6.6	90.4	(33.0-196.8)	Female	19	19.2	98.7	(59.4-154.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	6.8	nc	(nc-nc)	Male	236	267.1	88.3	(77.4-100.4)
Female	5	2.5	201.9	(65.1-471.3)	Female	276	296.3	93.2	(82.5-104.8)
<b><u>Lung and Bronchus</u></b>									
Male	33	36.3	90.9	(62.6-127.7)					
Female	42	41.9	100.3	(72.3-135.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Groton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	9.6	104.3	(49.9-191.8)	Male	3	6.8	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	Female	2	5.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	4	6.1	nc	(nc-nc)
Female	42	42.8	98.1	(70.7-132.7)	Female	3	4.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	4	5.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.0	nc	(nc-nc)
Male	17	11.6	146.4	(85.2-234.4)	<b><u>Ovary</u></b>				
Female	11	10.3	106.5	(53.1-190.6)	Female	5	3.8	132.9	(42.8-310.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	36	38.6	93.2	(65.2-129.0)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.4	nc	(nc-nc)
Male	4	6.0	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.4	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	8.6	105.2	(48.0-199.6)
Male	5	4.1	121.8	(39.3-284.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.8	nc	(nc-nc)	Female	10	9.5	105.1	(50.3-193.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.8	nc	(nc-nc)	Male	129	139.7	92.3	(77.1-109.7)
Female	1	1.0	nc	(nc-nc)	Female	115	134.7	85.4	(70.5-102.5)
<b><u>Lung and Bronchus</u></b>									
Male	13	17.7	73.4	(39.0-125.5)					
Female	9	17.0	53.0	(24.2-100.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	7.2	125.7	(57.4-238.7)	Male	7	4.7	149.3	(59.8-307.6)
Female	2	2.7	nc	(nc-nc)	Female	9	3.8	237.0	(108.1-449.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	4.2	192.7	(83.0-379.8)
Female	34	30.1	112.8	(78.1-157.7)	Female	6	3.6	164.9	(60.2-359.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.5	nc	(nc-nc)
Male	4	8.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	9	8.3	108.7	(49.6-206.4)	Female	3	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	1.9	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	22	26.2	83.8	(52.5-126.9)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.7	nc	(nc-nc)
Male	4	4.0	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.8	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	5.3	149.5	(64.4-294.7)
Male	4	2.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.2	nc	(nc-nc)	Female	4	6.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	93	96.7	96.1	(77.6-117.8)
Female	0	0.8	nc	(nc-nc)	Female	114	101.0	112.9	(93.1-135.7)
<b><u>Lung and Bronchus</u></b>									
Male	11	13.0	84.3	(42.0-150.9)					
Female	16	14.3	111.7	(63.8-181.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	7.2	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
Female	6	3.0	199.2	(72.7-433.5)	Female	3	3.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	3.9	179.5	(71.9-369.8)
Female	26	27.5	94.6	(61.8-138.6)	Female	5	3.7	134.1	(43.2-312.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	7	3.0	232.1	(93.0-478.3)
<b><u>Colon / Rectum</u></b>					Female	0	1.5	nc	(nc-nc)
Male	3	7.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	8	9.2	87.4	(37.6-172.3)	Female	2	2.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	18	24.1	74.6	(44.2-117.9)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.6	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	4.4	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.2	nc	(nc-nc)	Female	5	6.2	80.5	(25.9-187.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.3	nc	(nc-nc)	Male	68	91.1	74.7	(58.0-94.6)
Female	0	0.8	nc	(nc-nc)	Female	84	98.9	85.0	(67.8-105.2)
<b><u>Lung and Bronchus</u></b>									
Male	4	12.6	nc	(nc-nc)					
Female	10	14.4	69.2	(33.1-127.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Halifax

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	8.1	74.2	(27.1-161.4)	Male	6	5.4	111.2	(40.6-242.1)
Female	1	2.9	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.7	147.9	(59.2-304.7)
Female	37	33.9	109.1	(76.8-150.4)	Female	8	4.0	200.8	(86.5-395.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.7	nc	(nc-nc)
Male	14	9.1	153.7	(83.9-257.8)	<b><u>Ovary</u></b>				
Female	11	8.8	125.5	(62.6-224.6)	Female	5	3.1	163.7	(52.7-382.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	7	2.8	247.8	(99.3-510.6)
Female	0	0.6	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	37	31.0	119.2	(83.9-164.4)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.9	nc	(nc-nc)
Male	10	4.6	216.0	(103.4-397.2)	Female	1	1.1	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.0	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	7	2.1	327.5	(131.2-674.9)
<b><u>Leukemia</u></b>					Female	9	6.3	141.9	(64.7-269.3)
Male	1	3.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.3	nc	(nc-nc)	Female	11	7.9	139.8	(69.7-250.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	2.9	208.7	(76.2-454.3)	Male	145	111.8	129.7	(109.5-152.6)
Female	0	0.9	nc	(nc-nc)	Female	135	111.9	120.6	(101.2-142.8)
<b><u>Lung and Bronchus</u></b>									
Male	21	15.0	140.3	(86.8-214.5)					
Female	24	15.5	154.6	(99.0-230.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	7.8	114.8	(52.4-217.9)	Male	6	5.3	113.8	(41.5-247.7)
Female	3	2.7	nc	(nc-nc)	Female	5	4.1	122.2	(39.4-285.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.6	nc	(nc-nc)	Male	5	1.5	324.4	(104.5-757.1)
Female	3	1.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.6	150.6	(60.3-310.2)
Female	28	32.1	87.2	(57.9-126.0)	Female	7	3.7	187.9	(75.3-387.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	7	3.9	179.0	(71.7-368.8)
<b><u>Colon / Rectum</u></b>					Female	2	1.6	nc	(nc-nc)
Male	9	9.0	100.4	(45.8-190.6)	<b><u>Ovary</u></b>				
Female	9	8.3	108.0	(49.3-205.0)	Female	3	2.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.2	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	25	30.0	83.3	(53.9-123.0)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.9	nc	(nc-nc)
Male	7	4.5	154.6	(62.0-318.6)	Female	0	1.0	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.1	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	5	2.1	237.2	(76.4-553.5)
<b><u>Leukemia</u></b>					Female	8	6.1	130.6	(56.3-257.4)
Male	9	3.2	280.1	(127.8-531.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.2	nc	(nc-nc)	Female	8	7.3	109.2	(47.0-215.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.9	nc	(nc-nc)	Male	122	109.1	111.8	(92.9-133.5)
Female	0	0.8	nc	(nc-nc)	Female	108	105.2	102.6	(84.2-123.9)
<b><u>Lung and Bronchus</u></b>									
Male	13	14.5	89.8	(47.8-153.6)					
Female	10	14.2	70.5	(33.8-129.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	7.0	85.7	(31.3-186.5)	Male	4	4.4	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	5	3.3	150.1	(48.4-350.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.9	128.2	(41.3-299.2)
Female	26	26.5	98.0	(64.0-143.7)	Female	0	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.4	nc	(nc-nc)
Male	2	7.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	7.6	65.4	(21.1-152.7)	Female	1	2.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.9	nc	(nc-nc)	Male	5	2.4	209.0	(67.4-487.8)
Female	0	0.5	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	26	26.3	99.0	(64.7-145.1)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.6	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.4	114.6	(36.9-267.4)
Male	3	2.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.9	nc	(nc-nc)	Female	4	6.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	89	93.5	95.2	(76.4-117.1)
Female	0	0.8	nc	(nc-nc)	Female	73	90.5	80.7	(63.3-101.5)
<b><u>Lung and Bronchus</u></b>									
Male	14	12.9	108.8	(59.4-182.5)					
Female	10	13.1	76.6	(36.7-140.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.6	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	9	14.3	63.1	(28.8-119.7)
Female	0	0.1	nc	(nc-nc)	Female	9	11.7	76.6	(35.0-145.5)
<b><u>Lung and Bronchus</u></b>									
Male	0	2.0	nc	(nc-nc)					
Female	2	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hanover

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	13.8	72.7	(34.8-133.6)	Male	14	9.3	150.4	(82.2-252.4)
Female	3	5.2	nc	(nc-nc)	Female	8	7.6	105.3	(45.3-207.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.8	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	10	8.2	122.0	(58.4-224.4)
Female	74	60.5	122.3	(96.1-153.6)	Female	7	7.1	98.6	(39.5-203.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.1	nc	(nc-nc)	Male	6	6.9	86.6	(31.6-188.6)
<b><u>Colon / Rectum</u></b>					Female	1	3.0	nc	(nc-nc)
Male	17	15.7	108.1	(62.9-173.1)	<b><u>Ovary</u></b>				
Female	21	15.7	133.4	(82.5-203.9)	Female	4	5.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.9	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	3	5.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	56	53.7	104.2	(78.7-135.4)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	3.3	151.1	(48.7-352.5)
Male	6	8.1	74.1	(27.1-161.3)	Female	0	2.0	nc	(nc-nc)
Female	6	4.7	127.4	(46.5-277.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.8	nc	(nc-nc)
Male	5	2.2	229.3	(73.9-535.0)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	7	3.8	186.4	(74.7-384.0)
<b><u>Leukemia</u></b>					Female	12	11.1	107.9	(55.7-188.5)
Male	6	5.6	106.3	(38.8-231.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	4.2	nc	(nc-nc)	Female	16	13.8	116.1	(66.3-188.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.0	nc	(nc-nc)	Male	188	193.1	97.4	(83.9-112.3)
Female	0	1.6	nc	(nc-nc)	Female	211	199.3	105.8	(92.0-121.1)
<b><u>Lung and Bronchus</u></b>									
Male	21	25.7	81.8	(50.6-125.0)					
Female	32	27.8	115.1	(78.7-162.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hanson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	9.5	125.8	(65.0-219.8)	Male	4	6.6	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	6	5.2	115.5	(42.2-251.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.8	nc	(nc-nc)
Female	35	40.9	85.6	(59.6-119.0)	Female	5	4.6	108.9	(35.1-254.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	7	5.0	139.8	(56.0-288.0)
<b><u>Colon / Rectum</u></b>					Female	1	2.0	nc	(nc-nc)
Male	19	11.1	171.0	(102.9-267.1)	<b><u>Ovary</u></b>				
Female	10	9.9	101.5	(48.6-186.7)	Female	3	3.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	5	3.4	147.8	(47.6-344.8)
Female	1	0.6	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	48	38.6	124.5	(91.8-165.1)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.3	nc	(nc-nc)
Male	7	5.8	119.9	(48.0-247.0)	Female	1	1.2	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.4	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	16	8.2	196.1	(112.0-318.6)
Male	5	4.0	125.5	(40.5-293.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.7	nc	(nc-nc)	Female	20	9.4	211.9	(129.4-327.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.6	nc	(nc-nc)	Male	156	137.4	113.6	(96.4-132.8)
Female	4	1.0	nc	(nc-nc)	Female	139	131.4	105.8	(89.0-124.9)
<b><u>Lung and Bronchus</u></b>									
Male	25	18.0	139.1	(90.0-205.4)					
Female	17	17.4	97.6	(56.8-156.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	3.3	151.9	(48.9-354.4)	Male	2	2.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	13	11.8	110.3	(58.7-188.7)	Female	2	1.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.6	nc	(nc-nc)
Male	4	3.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	3.1	161.7	(52.1-377.3)	Female	0	1.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	8	12.3	65.2	(28.1-128.5)
Female	1	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.8	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.3	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.8	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	44	44.7	98.5	(71.5-132.2)
Female	0	0.3	nc	(nc-nc)	Female	40	39.1	102.3	(73.1-139.3)
<b><u>Lung and Bronchus</u></b>									
Male	8	6.0	133.0	(57.3-262.2)					
Female	7	5.3	131.8	(52.8-271.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Harvard

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	6.5	77.1	(24.8-179.9)	Male	7	4.8	147.1	(59.0-303.2)
Female	0	1.8	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	4.2	190.8	(82.1-375.9)
Female	17	24.5	69.4	(40.4-111.2)	Female	2	2.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.2	nc	(nc-nc)
Male	3	7.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	7	5.7	123.6	(49.5-254.8)	Female	2	2.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.0	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	20	28.0	71.5	(43.7-110.5)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.6	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.3	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	4.5	133.3	(48.7-290.2)
Male	5	2.8	180.5	(58.2-421.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.5	nc	(nc-nc)	Female	7	5.8	120.3	(48.2-247.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	78	98.2	79.5	(62.8-99.2)
Female	0	0.6	nc	(nc-nc)	Female	56	76.8	72.9	(55.1-94.7)
<b><u>Lung and Bronchus</u></b>									
Male	4	12.4	nc	(nc-nc)					
Female	4	10.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	38	24.4	155.6	(110.1-213.5)	Male	16	13.8	115.7	(66.1-187.9)
Female	8	9.0	88.8	(38.2-175.0)	Female	21	10.1	207.7	(128.5-317.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	5	4.3	117.1	(37.7-273.3)
Female	3	3.1	nc	(nc-nc)	Female	5	3.7	135.2	(43.6-315.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	14	12.2	115.0	(62.8-193.0)
Female	107	79.9	133.9	(109.7-161.8)	Female	10	11.0	90.9	(43.5-167.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.3	nc	(nc-nc)	Male	8	8.8	91.0	(39.2-179.3)
<b><u>Colon / Rectum</u></b>					Female	2	4.4	nc	(nc-nc)
Male	24	24.4	98.3	(63.0-146.3)	<b><u>Ovary</u></b>				
Female	34	26.1	130.1	(90.1-181.8)	Female	10	7.5	133.3	(63.8-245.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	5.9	84.7	(27.3-197.8)	Male	8	7.9	101.6	(43.8-200.2)
Female	2	1.7	nc	(nc-nc)	Female	9	8.8	101.8	(46.5-193.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	1.1	462.7	(149.1-1079.8)	Male	105	75.9	138.3	(113.1-167.5)
Female	1	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	5.3	188.0	(90.0-345.7)
Male	9	10.8	83.5	(38.1-158.5)	Female	3	3.3	nc	(nc-nc)
Female	7	6.9	102.0	(40.9-210.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.3	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	1.1	nc	(nc-nc)	Male	5	4.0	124.5	(40.1-290.6)
<b><u>Leukemia</u></b>					Female	1	11.2	nc	(nc-nc)
Male	11	8.5	129.3	(64.5-231.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	6.4	nc	(nc-nc)	Female	21	18.7	112.3	(69.5-171.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	6.9	nc	(nc-nc)	Male	351	289.0	121.5	(109.1-134.9)
Female	3	2.5	nc	(nc-nc)	Female	321	289.0	111.1	(99.3-123.9)
<b><u>Lung and Bronchus</u></b>									
Male	52	42.9	121.3	(90.6-159.1)					
Female	35	45.4	77.1	(53.7-107.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	4.8	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
Female	15	17.5	85.8	(48.0-141.5)	Female	1	2.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.9	nc	(nc-nc)
Male	5	5.2	95.8	(30.9-223.5)	<b><u>Ovary</u></b>				
Female	10	4.8	209.9	(100.5-386.0)	Female	3	1.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	16	17.7	90.2	(51.5-146.4)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.1	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	3.0	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.2	nc	(nc-nc)	Female	5	4.1	121.3	(39.1-283.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	59	63.7	92.6	(70.5-119.4)
Female	0	0.5	nc	(nc-nc)	Female	58	58.5	99.1	(75.3-128.1)
<b><u>Lung and Bronchus</u></b>									
Male	7	8.8	79.5	(31.8-163.8)					
Female	4	8.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	60	55.2	108.7	(82.9-139.9)	Male	36	37.4	96.3	(67.5-133.4)
Female	25	22.2	112.4	(72.7-165.9)	Female	27	33.3	81.0	(53.4-117.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	14	11.4	122.3	(66.8-205.2)	Male	8	10.7	74.5	(32.1-146.9)
Female	10	10.3	97.3	(46.6-179.0)	Female	8	9.5	84.3	(36.3-166.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	40	33.2	120.6	(86.1-164.2)
Female	253	247.4	102.2	(90.0-115.7)	Female	45	30.2	149.2	(108.8-199.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	9.2	65.4	(23.9-142.4)	Male	38	27.0	141.0	(99.8-193.5)
<b><u>Colon / Rectum</u></b>					Female	18	12.6	143.0	(84.7-226.0)
Male	81	63.2	128.2	(101.8-159.4)	<b><u>Ovary</u></b>				
Female	74	69.2	106.9	(84.0-134.2)	Female	23	22.6	101.7	(64.4-152.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	14	15.0	93.1	(50.8-156.2)	Male	25	19.0	131.3	(85.0-193.9)
Female	4	4.2	nc	(nc-nc)	Female	30	21.8	137.6	(92.8-196.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	7	5.1	136.0	(54.5-280.3)	Male	175	201.1	87.0	(74.6-100.9)
Female	4	4.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	21	13.2	159.1	(98.5-243.3)
Male	37	31.6	117.2	(82.5-161.6)	Female	8	8.7	91.7	(39.5-180.6)
Female	23	19.5	118.0	(74.8-177.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	9	9.1	98.4	(44.9-186.9)
Male	9	8.4	107.6	(49.1-204.3)	<b><u>Thyroid</u></b>				
Female	4	2.9	nc	(nc-nc)	Male	15	15.4	97.3	(54.4-160.5)
<b><u>Leukemia</u></b>					Female	48	49.4	97.1	(71.6-128.7)
Male	20	23.1	86.5	(52.8-133.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	19	18.5	102.6	(61.7-160.2)	Female	61	55.5	109.9	(84.1-141.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	18	19.6	91.9	(54.5-145.3)	Male	785	758.4	103.5	(96.4-111.0)
Female	4	6.7	nc	(nc-nc)	Female	908	838.5	108.3	(101.4-115.6)
<b><u>Lung and Bronchus</u></b>									
Male	106	99.7	106.3	(87.0-128.6)					
Female	145	113.2	128.1	(108.1-150.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	7.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	5	5.7	87.8	(28.3-205.0)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.1	nc	(nc-nc)					
Female	1	0.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	3.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	6	4.4	136.1	(49.7-296.3)
Female	2	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.6	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	15	15.5	96.8	(54.1-159.7)
Female	0	0.1	nc	(nc-nc)	Female	8	12.2	65.6	(28.2-129.3)
<b><u>Lung and Bronchus</u></b>									
Male	3	2.1	nc	(nc-nc)					
Female	1	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	29.8	83.9	(54.3-123.9)	Male	37	17.9	206.3	(145.3-284.4)
Female	10	12.2	81.8	(39.2-150.5)	Female	28	14.7	191.0	(126.9-276.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	4.9	nc	(nc-nc)	Male	6	5.4	111.1	(40.6-241.8)
Female	5	4.7	107.5	(34.6-250.8)	Female	5	5.0	99.3	(32.0-231.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	18	16.0	112.7	(66.8-178.2)
Female	112	114.1	98.1	(80.8-118.1)	Female	28	15.3	183.3	(121.8-265.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.6	nc	(nc-nc)	Male	16	12.0	132.9	(75.9-215.9)
<b><u>Colon / Rectum</u></b>					Female	8	6.2	129.5	(55.7-255.1)
Male	26	31.5	82.5	(53.9-120.9)	<b><u>Ovary</u></b>				
Female	44	37.1	118.7	(86.3-159.4)	Female	14	10.6	132.4	(72.3-222.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	7.4	80.7	(29.5-175.6)	Male	5	9.8	51.1	(16.5-119.2)
Female	4	2.3	nc	(nc-nc)	Female	10	12.1	82.7	(39.6-152.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	110	95.7	114.9	(94.4-138.5)
Female	2	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	6.7	nc	(nc-nc)
Male	12	14.4	83.1	(42.9-145.1)	Female	1	4.7	nc	(nc-nc)
Female	12	9.5	126.1	(65.1-220.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.5	nc	(nc-nc)
Male	2	4.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	6	6.0	99.7	(36.4-217.0)
<b><u>Leukemia</u></b>					Female	26	18.0	144.3	(94.2-211.4)
Male	12	11.3	106.5	(55.0-186.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	9.3	129.4	(66.8-226.0)	Female	20	25.6	78.2	(47.8-120.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	9.1	nc	(nc-nc)	Male	354	369.2	95.9	(86.2-106.4)
Female	0	3.4	nc	(nc-nc)	Female	421	406.1	103.7	(94.0-114.1)
<b><u>Lung and Bronchus</u></b>									
Male	34	52.2	65.2	(45.1-91.1)					
Female	44	59.7	73.7	(53.5-98.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	16	10.0	160.6	(91.7-260.7)	Female	2	1.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.5	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.6	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	10.7	46.8	(15.1-109.2)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.7	nc	(nc-nc)
Male	4	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	1.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	5	2.4	212.4	(68.4-495.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	36	38.5	93.5	(65.4-129.4)
Female	0	0.3	nc	(nc-nc)	Female	44	33.1	132.8	(96.5-178.3)
<b><u>Lung and Bronchus</u></b>									
Male	11	5.4	204.4	(101.9-365.7)					
Female	7	4.8	147.2	(59.0-303.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holbrook

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	12.0	183.1	(114.7-277.2)	Male	4	7.8	nc	(nc-nc)
Female	9	4.3	207.2	(94.6-393.4)	Female	11	6.2	177.7	(88.6-318.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.2	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	5	1.9	269.9	(87.0-629.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	11	6.9	159.7	(79.6-285.8)
Female	50	47.3	105.6	(78.4-139.3)	Female	7	5.8	120.3	(48.2-247.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.7	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	2.4	nc	(nc-nc)
Male	17	13.3	128.2	(74.7-205.3)	<b><u>Ovary</u></b>				
Female	17	13.3	128.1	(74.6-205.1)	Female	7	4.3	162.6	(65.1-334.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	3.2	187.7	(68.5-408.5)	Male	6	4.1	147.4	(53.8-320.9)
Female	1	0.8	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	54	42.3	127.8	(96.0-166.7)
Female	2	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	2.8	nc	(nc-nc)
Male	8	6.5	122.9	(52.9-242.3)	Female	1	1.7	nc	(nc-nc)
Female	5	3.8	132.5	(42.7-309.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.6	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	8.8	90.5	(39.0-178.3)
Male	5	4.8	105.2	(33.9-245.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	3.5	200.8	(80.5-413.8)	Female	10	10.7	93.4	(44.7-171.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	4.1	196.5	(84.6-387.2)	Male	204	159.4	128.0	(111.0-146.8)
Female	1	1.3	nc	(nc-nc)	Female	204	160.7	126.9	(110.1-145.6)
<b><u>Lung and Bronchus</u></b>									
Male	24	21.9	109.7	(70.3-163.3)					
Female	45	22.7	198.6	(144.8-265.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	19.5	97.5	(58.7-152.3)	Male	21	12.7	165.5	(102.4-253.0)
Female	6	7.0	85.9	(31.4-187.0)	Female	6	9.9	60.4	(22.1-131.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.7	nc	(nc-nc)	Male	5	3.7	133.6	(43.1-311.9)
Female	5	3.1	160.9	(51.9-375.6)	Female	2	3.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	9	11.2	80.5	(36.7-152.8)
Female	81	77.3	104.8	(83.2-130.2)	Female	7	9.4	74.4	(29.8-153.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.7	nc	(nc-nc)	Male	13	9.1	142.2	(75.6-243.1)
<b><u>Colon / Rectum</u></b>					Female	5	3.9	126.8	(40.9-295.9)
Male	15	21.7	69.1	(38.7-114.0)	<b><u>Ovary</u></b>				
Female	23	21.4	107.4	(68.1-161.2)	Female	7	7.0	99.7	(39.9-205.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	5.3	151.3	(65.1-298.2)	Male	10	6.7	149.6	(71.6-275.1)
Female	1	1.3	nc	(nc-nc)	Female	2	6.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	73	71.3	102.3	(80.2-128.7)
Female	2	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	4.6	nc	(nc-nc)
Male	7	10.7	65.4	(26.2-134.7)	Female	2	2.7	nc	(nc-nc)
Female	7	6.1	114.7	(45.9-236.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	2.3	264.5	(96.6-575.6)
Male	2	2.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	14.2	56.5	(24.3-111.3)
Male	8	7.7	103.6	(44.6-204.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	5.6	nc	(nc-nc)	Female	27	17.6	153.0	(100.8-222.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	6.8	73.8	(23.8-172.2)	Male	269	262.1	102.6	(90.7-115.7)
Female	3	2.1	nc	(nc-nc)	Female	255	260.2	98.0	(86.3-110.8)
<b><u>Lung and Bronchus</u></b>									
Male	37	35.4	104.4	(73.5-143.9)					
Female	28	36.2	77.4	(51.4-111.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	2.6	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	3	0.7	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	5	9.8	51.0	(16.4-119.1)	Female	1	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.5	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	10	11.2	89.6	(42.9-164.9)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	2.0	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.6	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	26	38.5	67.6	(44.2-99.1)
Female	0	0.2	nc	(nc-nc)	Female	33	31.1	106.1	(73.0-149.0)
<b><u>Lung and Bronchus</u></b>									
Male	4	5.0	nc	(nc-nc)					
Female	5	4.0	124.1	(40.0-289.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	13.9	107.8	(60.3-177.8)	Male	10	9.5	105.3	(50.4-193.6)
Female	2	4.7	nc	(nc-nc)	Female	4	7.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	2.8	176.7	(56.9-412.3)	Male	3	2.8	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	9	8.4	107.7	(49.1-204.5)
Female	63	59.0	106.8	(82.1-136.7)	Female	3	6.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.1	nc	(nc-nc)	Male	7	7.2	97.5	(39.0-200.8)
<b><u>Colon / Rectum</u></b>					Female	3	2.9	nc	(nc-nc)
Male	18	16.1	111.9	(66.3-176.8)	<b><u>Ovary</u></b>				
Female	13	14.7	88.7	(47.2-151.7)	Female	4	5.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	4.0	174.7	(70.0-359.9)	Male	4	4.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	72	55.4	130.0	(101.7-163.7)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.4	nc	(nc-nc)
Male	8	8.3	96.2	(41.4-189.6)	Female	1	1.8	nc	(nc-nc)
Female	4	4.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.8	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	11.1	99.2	(49.5-177.5)
Male	7	5.7	123.3	(49.4-254.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.9	nc	(nc-nc)	Female	22	13.6	161.4	(101.1-244.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	5.2	95.5	(30.8-222.8)	Male	219	197.4	111.0	(96.7-126.7)
Female	1	1.5	nc	(nc-nc)	Female	180	190.6	94.4	(81.1-109.3)
<b><u>Lung and Bronchus</u></b>									
Male	15	26.1	57.6	(32.2-94.9)					
Female	21	25.9	81.1	(50.2-124.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	33	40.4	81.8	(56.3-114.9)	Male	20	25.2	79.4	(48.5-122.7)
Female	13	16.1	80.6	(42.9-137.9)	Female	15	21.9	68.4	(38.2-112.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	7.5	106.7	(46.0-210.4)	Male	3	7.4	nc	(nc-nc)
Female	4	7.0	nc	(nc-nc)	Female	1	6.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	19	22.5	84.3	(50.7-131.6)
Female	124	158.8	78.1	(64.9-93.1)	Female	17	20.9	81.4	(47.4-130.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	12	5.6	213.7	(110.3-373.4)	Male	25	17.0	146.8	(95.0-216.7)
<b><u>Colon / Rectum</u></b>					Female	6	8.5	70.7	(25.8-153.9)
Male	38	43.6	87.2	(61.7-119.7)	<b><u>Ovary</u></b>				
Female	46	49.5	93.0	(68.1-124.0)	Female	15	14.9	100.6	(56.3-166.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	10.2	78.6	(33.8-154.9)	Male	15	13.4	111.7	(62.5-184.2)
Female	3	3.0	nc	(nc-nc)	Female	25	16.0	156.4	(101.2-230.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	3.2	nc	(nc-nc)	Male	116	132.0	87.9	(72.6-105.4)
Female	4	3.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	9.2	nc	(nc-nc)
Male	21	20.3	103.5	(64.1-158.3)	Female	9	6.3	142.0	(64.8-269.5)
Female	8	13.1	61.2	(26.4-120.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	5.5	nc	(nc-nc)
Male	8	5.6	144.1	(62.1-284.0)	<b><u>Thyroid</u></b>				
Female	2	1.9	nc	(nc-nc)	Male	3	9.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	19	30.1	63.1	(38.0-98.5)
Male	12	16.3	73.8	(38.1-128.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	13.2	76.0	(36.4-139.7)	Female	42	35.6	118.1	(85.1-159.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	24	12.7	189.1	(121.1-281.4)	Male	488	514.5	94.9	(86.6-103.7)
Female	7	4.6	150.9	(60.5-311.0)	Female	499	563.4	88.6	(81.0-96.7)
<b><u>Lung and Bronchus</u></b>									
Male	74	70.5	105.0	(82.5-131.9)					
Female	71	78.8	90.1	(70.4-113.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	6.3	111.8	(44.8-230.5)	Male	7	4.1	172.3	(69.0-355.1)
Female	1	2.4	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	24	25.7	93.4	(59.8-139.0)	Female	0	3.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.3	nc	(nc-nc)
Male	5	7.1	70.8	(22.8-165.3)	<b><u>Ovary</u></b>				
Female	12	7.5	159.9	(82.5-279.3)	Female	2	2.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	1.6	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	28	21.0	133.4	(88.6-192.8)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.5	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.8	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	4.8	125.6	(45.9-273.5)
Male	4	2.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.9	nc	(nc-nc)	Female	7	5.7	123.7	(49.6-254.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	90	82.0	109.8	(88.3-134.9)
Female	0	0.7	nc	(nc-nc)	Female	77	87.2	88.3	(69.7-110.3)
<b><u>Lung and Bronchus</u></b>									
Male	11	11.0	100.4	(50.0-179.6)					
Female	14	11.9	118.1	(64.5-198.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	11.0	73.0	(31.4-143.8)	Male	14	8.3	169.7	(92.7-284.7)
Female	6	3.8	157.7	(57.6-343.2)	Female	11	6.9	159.2	(79.4-284.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	2.7	291.7	(125.6-574.7)	Male	1	2.3	nc	(nc-nc)
Female	5	2.2	227.9	(73.5-531.9)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.3	68.1	(21.9-158.9)
Female	52	55.2	94.2	(70.4-123.6)	Female	6	5.8	104.1	(38.0-226.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.1	nc	(nc-nc)	Male	6	6.6	90.4	(33.0-196.7)
<b><u>Colon / Rectum</u></b>					Female	1	2.5	nc	(nc-nc)
Male	7	13.8	50.6	(20.3-104.2)	<b><u>Ovary</u></b>				
Female	13	12.6	103.2	(54.9-176.5)	Female	2	4.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	6	3.7	163.8	(59.8-356.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	57	46.7	122.0	(92.4-158.1)
Female	2	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	2.8	176.8	(57.0-412.7)
Male	5	7.5	66.6	(21.5-155.5)	Female	0	1.5	nc	(nc-nc)
Female	1	4.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.9	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	5	3.8	130.4	(42.0-304.3)
<b><u>Leukemia</u></b>					Female	17	11.7	145.7	(84.8-233.3)
Male	4	5.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	3.5	nc	(nc-nc)	Female	10	12.1	82.8	(39.6-152.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	4.6	nc	(nc-nc)	Male	156	168.3	92.7	(78.7-108.5)
Female	2	1.3	nc	(nc-nc)	Female	171	170.7	100.2	(85.7-116.4)
<b><u>Lung and Bronchus</u></b>									
Male	9	20.8	43.4	(19.8-82.3)					
Female	19	20.9	91.0	(54.8-142.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	4.1	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	22	16.7	131.9	(82.6-199.7)	Female	1	1.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	5	0.8	638.0	(205.6-1489.0)
Male	1	4.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	6	3.8	158.5	(57.9-345.0)	Female	3	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	12	16.9	71.1	(36.7-124.2)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.0	nc	(nc-nc)
Male	4	2.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	3.5	170.8	(62.4-371.8)
Male	1	1.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	5	3.8	132.6	(42.7-309.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	43	59.9	71.8	(51.9-96.7)
Female	0	0.4	nc	(nc-nc)	Female	64	51.9	123.4	(95.0-157.5)
<b><u>Lung and Bronchus</u></b>									
Male	4	7.7	nc	(nc-nc)					
Female	5	6.4	77.8	(25.1-181.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	20.9	105.2	(65.9-159.2)	Male	11	13.7	80.0	(39.9-143.2)
Female	8	7.4	108.7	(46.8-214.2)	Female	9	10.8	83.7	(38.2-158.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.0	150.0	(54.8-326.4)	Male	2	4.0	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	8	12.1	66.3	(28.5-130.6)
Female	84	83.3	100.9	(80.5-124.9)	Female	7	10.0	70.0	(28.0-144.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.9	nc	(nc-nc)	Male	14	9.7	143.8	(78.6-241.3)
<b><u>Colon / Rectum</u></b>					Female	4	4.2	nc	(nc-nc)
Male	30	23.2	129.3	(87.2-184.6)	<b><u>Ovary</u></b>				
Female	23	22.2	103.7	(65.7-155.6)	Female	11	7.5	146.8	(73.2-262.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	5.7	141.3	(60.8-278.5)	Male	5	7.1	70.0	(22.5-163.3)
Female	1	1.4	nc	(nc-nc)	Female	7	7.1	98.9	(39.6-203.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	81	75.8	106.9	(84.9-132.9)
Female	1	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.9	nc	(nc-nc)
Male	7	11.5	60.7	(24.3-125.0)	Female	5	2.7	181.9	(58.6-424.5)
Female	9	6.6	136.0	(62.1-258.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.8	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	22	15.7	140.3	(87.9-212.5)
Male	9	8.4	107.8	(49.2-204.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	5.9	nc	(nc-nc)	Female	26	19.0	137.1	(89.5-200.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	7.2	69.6	(22.4-162.4)	Male	276	281.4	98.1	(86.8-110.3)
Female	0	2.3	nc	(nc-nc)	Female	281	279.0	100.7	(89.3-113.2)
<b><u>Lung and Bronchus</u></b>									
Male	36	38.3	94.0	(65.9-130.2)					
Female	36	39.7	90.6	(63.4-125.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hull

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	12.4	145.0	(85.9-229.1)	Male	11	8.3	132.7	(66.1-237.4)
Female	5	4.5	110.3	(35.5-257.3)	Female	11	6.8	162.4	(81.0-290.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	7	7.2	97.2	(38.9-200.2)
Female	56	54.6	102.6	(77.5-133.2)	Female	10	6.3	158.8	(76.0-292.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.8	nc	(nc-nc)	Male	3	6.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	6	2.7	221.1	(80.7-481.2)
Male	10	14.0	71.4	(34.2-131.4)	<b><u>Ovary</u></b>				
Female	9	13.7	65.8	(30.0-125.0)	Female	4	4.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	3.6	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	7	4.4	160.4	(64.3-330.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	53	50.0	105.9	(79.3-138.5)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.0	nc	(nc-nc)
Male	10	7.2	138.8	(66.5-255.3)	Female	0	1.7	nc	(nc-nc)
Female	6	4.2	142.6	(52.1-310.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.4	nc	(nc-nc)
Male	5	2.0	250.3	(80.7-584.2)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	9.7	nc	(nc-nc)
Male	1	4.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.5	nc	(nc-nc)	Female	15	13.0	115.1	(64.3-189.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	4.6	303.0	(165.5-508.4)	Male	198	174.2	113.6	(98.4-130.6)
Female	1	1.5	nc	(nc-nc)	Female	195	177.8	109.7	(94.8-126.2)
<b><u>Lung and Bronchus</u></b>									
Male	28	23.4	119.9	(79.6-173.3)					
Female	33	24.9	132.4	(91.1-185.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	7	9.0	78.2	(31.3-161.1)	Female	2	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	2.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	9.6	62.7	(22.9-136.5)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.6	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	2	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	1.8	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	38	33.1	114.8	(81.2-157.6)
Female	1	0.2	nc	(nc-nc)	Female	23	29.0	79.4	(50.3-119.2)
<b><u>Lung and Bronchus</u></b>									
Male	6	4.2	141.6	(51.7-308.1)					
Female	3	3.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ipswich

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	17.3	126.9	(79.5-192.1)	Male	15	11.0	136.4	(76.3-224.9)
Female	8	6.7	119.8	(51.6-236.1)	Female	9	8.7	103.1	(47.1-195.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.0	165.7	(53.4-386.7)	Male	2	3.3	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	8	9.7	82.7	(35.6-163.0)
Female	82	69.2	118.5	(94.3-147.2)	Female	9	8.7	103.7	(47.3-196.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.2	nc	(nc-nc)	Male	8	7.9	101.2	(43.6-199.5)
<b><u>Colon / Rectum</u></b>					Female	5	3.6	138.7	(44.7-323.6)
Male	10	18.9	52.9	(25.3-97.2)	<b><u>Ovary</u></b>				
Female	18	20.2	89.3	(52.9-141.1)	Female	9	6.3	142.1	(64.9-269.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	4.7	106.4	(34.3-248.3)	Male	8	5.9	135.4	(58.3-266.7)
Female	2	1.3	nc	(nc-nc)	Female	9	6.5	138.0	(63.0-261.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	77	63.5	121.2	(95.6-151.5)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	4.0	nc	(nc-nc)
Male	7	9.2	75.7	(30.3-155.9)	Female	6	2.5	236.6	(86.4-515.0)
Female	7	5.6	125.7	(50.3-258.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.7	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	5	4.0	124.8	(40.2-291.3)
<b><u>Leukemia</u></b>					Female	10	11.4	87.5	(41.9-160.9)
Male	8	6.6	121.1	(52.1-238.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	5.1	157.4	(67.8-310.2)	Female	18	16.0	112.5	(66.6-177.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.9	nc	(nc-nc)	Male	247	229.9	107.5	(94.5-121.7)
Female	5	2.0	252.0	(81.2-588.2)	Female	255	236.7	107.7	(94.9-121.8)
<b><u>Lung and Bronchus</u></b>									
Male	32	31.6	101.3	(69.3-143.0)					
Female	27	34.2	79.0	(52.0-114.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	13.3	97.4	(51.8-166.6)	Male	12	8.8	136.9	(70.7-239.1)
Female	6	5.6	106.8	(39.0-232.4)	Female	11	7.5	146.6	(73.1-262.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.6	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	7.7	nc	(nc-nc)
Female	64	57.9	110.6	(85.2-141.2)	Female	9	7.3	123.2	(56.2-233.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.0	nc	(nc-nc)	Male	6	6.3	94.6	(34.5-205.9)
<b><u>Colon / Rectum</u></b>					Female	2	3.0	nc	(nc-nc)
Male	14	15.0	93.2	(50.9-156.5)	<b><u>Ovary</u></b>				
Female	15	17.3	86.6	(48.4-142.8)	Female	2	5.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	3.6	nc	(nc-nc)	Male	13	4.6	283.1	(150.6-484.2)
Female	4	1.1	nc	(nc-nc)	Female	8	5.5	144.2	(62.1-284.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	47	49.0	95.9	(70.5-127.6)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	3.2	253.3	(109.1-499.1)
Male	8	7.4	107.6	(46.3-212.1)	Female	0	2.2	nc	(nc-nc)
Female	4	4.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.7	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	15	10.2	146.6	(82.0-241.8)
Male	7	5.3	130.9	(52.5-269.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	4.4	112.4	(36.2-262.3)	Female	17	12.9	131.7	(76.7-210.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.6	nc	(nc-nc)	Male	186	180.6	103.0	(88.7-118.9)
Female	1	1.6	nc	(nc-nc)	Female	215	199.2	107.9	(94.0-123.4)
<b><u>Lung and Bronchus</u></b>									
Male	30	24.3	123.6	(83.4-176.4)					
Female	23	27.8	82.8	(52.5-124.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	10.8	120.3	(64.0-205.8)	Male	7	7.4	95.2	(38.1-196.2)
Female	4	3.7	nc	(nc-nc)	Female	4	5.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	2.2	227.4	(73.3-530.8)	Male	1	2.2	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	7	6.5	107.9	(43.2-222.4)
Female	42	45.2	92.9	(66.9-125.6)	Female	3	5.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	6	5.5	108.4	(39.6-235.8)
<b><u>Colon / Rectum</u></b>					Female	4	2.2	nc	(nc-nc)
Male	17	12.4	136.8	(79.6-219.0)	<b><u>Ovary</u></b>				
Female	11	11.6	94.9	(47.3-169.8)	Female	4	4.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.1	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	5	3.6	138.8	(44.7-323.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	43	42.7	100.6	(72.8-135.6)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	2.6	191.4	(61.7-446.7)
Male	5	6.4	77.9	(25.1-181.7)	Female	1	1.4	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.4	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	8.7	138.4	(71.4-241.8)
Male	3	4.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.1	nc	(nc-nc)	Female	13	10.2	127.0	(67.6-217.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	4.0	nc	(nc-nc)	Male	157	152.7	102.8	(87.4-120.2)
Female	1	1.2	nc	(nc-nc)	Female	143	147.2	97.1	(81.9-114.4)
<b><u>Lung and Bronchus</u></b>									
Male	14	20.1	69.5	(38.0-116.6)					
Female	14	19.7	70.9	(38.7-119.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	7.3	176.9	(94.1-302.5)	Male	6	5.3	114.1	(41.7-248.4)
Female	5	2.7	187.6	(60.5-437.8)	Female	3	3.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.7	107.0	(34.5-249.7)
Female	28	30.0	93.3	(62.0-134.9)	Female	3	3.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.5	nc	(nc-nc)
Male	5	8.6	58.0	(18.7-135.4)	<b><u>Ovary</u></b>				
Female	3	8.1	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	46	27.9	164.6	(120.5-219.5)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.8	nc	(nc-nc)
Male	5	4.5	111.2	(35.8-259.5)	Female	0	1.0	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.6	nc	(nc-nc)
Male	4	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	5.6	89.6	(28.9-209.0)
Male	3	3.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.1	nc	(nc-nc)	Female	4	6.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.7	nc	(nc-nc)	Male	122	105.4	115.8	(96.1-138.2)
Female	2	0.8	nc	(nc-nc)	Female	84	100.5	83.6	(66.7-103.5)
<b><u>Lung and Bronchus</u></b>									
Male	10	13.6	73.6	(35.3-135.4)					
Female	9	14.0	64.5	(29.4-122.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	4.0	nc	(nc-nc)	Male	6	2.6	230.8	(84.3-502.4)
Female	0	1.3	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	9	15.0	60.1	(27.4-114.2)	Female	3	1.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.8	nc	(nc-nc)
Male	4	4.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	3.9	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	14	15.5	90.6	(49.5-152.0)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.9	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.4	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	2.7	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.0	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	53	54.7	96.9	(72.6-126.8)
Female	0	0.4	nc	(nc-nc)	Female	32	49.3	64.9	(44.4-91.6)
<b><u>Lung and Bronchus</u></b>									
Male	9	7.4	121.5	(55.4-230.6)					
Female	5	6.9	72.9	(23.5-170.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lawrence

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	49	49.7	98.7	(73.0-130.5)	Male	13	35.3	36.8	(19.6-63.0)
Female	16	19.8	80.7	(46.1-131.1)	Female	13	33.7	38.5	(20.5-65.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	12.3	65.2	(28.1-128.6)	Male	10	9.8	101.8	(48.7-187.2)
Female	10	11.0	91.1	(43.6-167.5)	Female	16	8.6	186.5	(106.5-302.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	29	31.7	91.5	(61.3-131.4)
Female	176	239.3	73.6	(63.1-85.3)	Female	33	28.4	116.3	(80.0-163.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	17	9.7	174.7	(101.7-279.8)	Male	28	25.5	109.9	(73.0-158.9)
<b><u>Colon / Rectum</u></b>					Female	11	11.9	92.4	(46.1-165.3)
Male	60	58.1	103.3	(78.8-132.9)	<b><u>Ovary</u></b>				
Female	59	62.5	94.4	(71.8-121.7)	Female	11	21.9	50.3	(25.1-90.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	13.8	72.5	(34.7-133.4)	Male	19	17.3	109.7	(66.0-171.4)
Female	9	3.8	236.1	(107.8-448.3)	Female	16	19.3	82.9	(47.3-134.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	6.2	nc	(nc-nc)	Male	243	185.3	131.1	(115.1-148.7)
Female	5	5.5	90.5	(29.2-211.2)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	22	12.1	182.4	(114.3-276.2)
Male	20	30.0	66.6	(40.7-102.9)	Female	11	7.8	140.3	(70.0-251.1)
Female	17	18.6	91.2	(53.1-146.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	9	11.7	77.0	(35.1-146.2)
Male	9	7.7	117.1	(53.4-222.3)	<b><u>Thyroid</u></b>				
Female	4	2.8	nc	(nc-nc)	Male	17	15.9	107.0	(62.3-171.3)
<b><u>Leukemia</u></b>					Female	60	54.5	110.0	(83.9-141.6)
Male	18	23.0	78.2	(46.3-123.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	21	18.4	114.1	(70.6-174.4)	Female	45	53.0	84.9	(61.9-113.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	27	18.2	148.6	(97.9-216.2)	Male	736	710.0	103.7	(96.3-111.4)
Female	14	6.2	225.0	(122.9-377.6)	Female	708	802.6	88.2	(81.8-95.0)
<b><u>Lung and Bronchus</u></b>									
Male	86	90.2	95.4	(76.3-117.8)					
Female	89	103.6	85.9	(69.0-105.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lee

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	8.2	183.3	(102.5-302.4)	Male	7	5.1	137.4	(55.1-283.2)
Female	2	3.1	nc	(nc-nc)	Female	9	3.9	229.8	(104.9-436.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	4	1.2	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
Female	24	30.2	79.4	(50.8-118.1)	Female	4	3.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	0	3.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.6	nc	(nc-nc)
Male	6	8.7	68.6	(25.0-149.3)	<b><u>Ovary</u></b>				
Female	8	9.2	87.0	(37.5-171.4)	Female	0	2.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.1	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	32	28.7	111.5	(76.3-157.4)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.9	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.8	nc	(nc-nc)
Male	4	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.4	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	5.0	139.2	(55.8-286.7)
Male	2	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	2.3	nc	(nc-nc)	Female	3	7.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.6	nc	(nc-nc)	Male	114	105.7	107.8	(88.9-129.5)
Female	2	0.9	nc	(nc-nc)	Female	98	105.7	92.7	(75.2-113.0)
<b><u>Lung and Bronchus</u></b>									
Male	17	14.8	115.0	(66.9-184.1)					
Female	18	15.4	116.5	(69.0-184.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	11.3	88.6	(42.4-162.9)	Male	11	7.5	145.9	(72.7-261.1)
Female	3	4.1	nc	(nc-nc)	Female	10	6.0	165.8	(79.4-305.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	4	6.7	nc	(nc-nc)
Female	54	46.1	117.1	(88.0-152.8)	Female	4	5.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	1.6	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.3	nc	(nc-nc)
Male	10	12.7	78.6	(37.7-144.6)	<b><u>Ovary</u></b>				
Female	10	12.6	79.5	(38.1-146.3)	Female	4	4.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.1	nc	(nc-nc)	Male	0	3.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	6	4.0	150.2	(54.8-326.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	30	42.6	70.4	(47.5-100.5)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.7	nc	(nc-nc)
Male	5	6.4	77.8	(25.1-181.5)	Female	0	1.6	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.6	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	8.8	nc	(nc-nc)
Male	7	4.6	153.7	(61.6-316.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.3	nc	(nc-nc)	Female	14	10.5	134.0	(73.2-224.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	4.0	nc	(nc-nc)	Male	139	155.5	89.4	(75.2-105.6)
Female	0	1.3	nc	(nc-nc)	Female	166	155.1	107.0	(91.3-124.6)
<b><u>Lung and Bronchus</u></b>									
Male	29	20.8	139.7	(93.5-200.6)					
Female	30	21.7	138.6	(93.5-197.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	9.1	143.4	(76.3-245.2)	Male	9	5.1	176.6	(80.6-335.2)
Female	1	4.1	nc	(nc-nc)	Female	5	4.3	116.3	(37.5-271.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
Female	37	32.5	113.8	(80.1-156.8)	Female	3	4.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.9	nc	(nc-nc)
Male	16	9.2	174.4	(99.6-283.3)	<b><u>Ovary</u></b>				
Female	16	12.5	128.5	(73.4-208.6)	Female	5	3.2	158.6	(51.1-370.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	30	26.8	111.8	(75.4-159.6)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.0	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	4.3	nc	(nc-nc)
Male	7	3.2	217.9	(87.3-448.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.9	nc	(nc-nc)	Female	10	7.3	136.1	(65.2-250.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	106	105.6	100.4	(82.2-121.4)
Female	2	1.1	nc	(nc-nc)	Female	120	123.3	97.3	(80.7-116.4)
<b><u>Lung and Bronchus</u></b>									
Male	9	15.5	58.2	(26.6-110.5)					
Female	14	18.5	75.5	(41.3-126.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	52	42.4	122.7	(91.6-160.9)	Male	21	27.8	75.6	(46.8-115.6)
Female	27	16.6	163.0	(107.4-237.1)	Female	21	23.3	90.3	(55.9-138.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	8.2	97.9	(42.1-192.9)	Male	12	8.1	148.3	(76.6-259.1)
Female	8	7.2	111.6	(48.0-219.8)	Female	6	7.0	85.9	(31.4-187.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	28	24.6	113.8	(75.6-164.5)
Female	165	174.6	94.5	(80.6-110.1)	Female	24	21.9	109.6	(70.2-163.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	6.2	129.6	(55.8-255.4)	Male	19	19.6	96.7	(58.2-151.1)
<b><u>Colon / Rectum</u></b>					Female	12	9.0	132.7	(68.5-231.8)
Male	42	47.2	88.9	(64.1-120.2)	<b><u>Ovary</u></b>				
Female	37	50.8	72.8	(51.3-100.4)	Female	24	16.1	149.5	(95.8-222.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	11.3	97.2	(48.5-174.0)	Male	16	14.4	111.0	(63.4-180.2)
Female	3	3.1	nc	(nc-nc)	Female	16	16.2	98.5	(56.3-160.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	3.5	nc	(nc-nc)	Male	155	150.0	103.3	(87.7-120.9)
Female	5	3.0	168.3	(54.2-392.7)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	10.0	100.4	(48.1-184.7)
Male	20	23.2	86.3	(52.7-133.3)	Female	6	6.4	93.2	(34.0-202.8)
Female	14	14.0	100.1	(54.7-167.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	5.9	nc	(nc-nc)
Male	8	6.3	127.6	(54.9-251.4)	<b><u>Thyroid</u></b>				
Female	1	2.1	nc	(nc-nc)	Male	7	10.8	64.6	(25.9-133.2)
<b><u>Leukemia</u></b>					Female	19	32.9	57.8	(34.8-90.2)
Male	18	17.1	105.3	(62.4-166.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	13.3	90.5	(46.7-158.0)	Female	38	39.2	96.9	(68.5-133.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	14.5	41.5	(15.2-90.3)	Male	573	566.4	101.2	(93.1-109.8)
Female	2	4.9	nc	(nc-nc)	Female	563	600.4	93.8	(86.2-101.8)
<b><u>Lung and Bronchus</u></b>									
Male	95	76.5	124.2	(100.5-151.8)					
Female	72	83.8	85.9	(67.2-108.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;